The quantitative comparison study compared 4 different, commercially available enzyme-linked immunosorbent assays used in therapeutic drug monitoring to detect drug concentration and antibodies to infliximab in samples of drug diluted in serum.
Investigators said they have determined that assays used to evaluate circulating drug levels and antibody resistance for the Remicade version of infliximab are also appropriate for 2 infliximab biosimilars, SB2 (Renflexis) and CT-P13 (Inflectra).
The quantitative comparison study compared 4 different, commercially available enzyme-linked immunosorbent assays (ELISAs) used in therapeutic drug monitoring (TDM) to detect drug concentration and antibodies to infliximab (ATIs) in samples of drug diluted in serum. The findings showed the measurements for SB2 and CT-P13 were “comparable to those of the reference infliximab” for each of the assays, the authors wrote.
“The therapeutic drug monitoring required for infliximab therapy can be adequately performed with the biosimilars using the kits currently in use or available in clinical laboratories,” they concluded.
TDM is the measurement of specific drugs and their breakdown by analyzing serum trough levels at timed intervals. Measurements help to guide adjustments in treatment intensity to minimize the risk of treatment failure.
Variability in circulating drug levels is attributed to drug metabolism, leakage through the intestinal wall, or formation of antibodies against the drug. Commercial assays that measure antibodies to infliximab are routinely used as part of drug monitoring.
The biosimilars SB2 and CT-P13 are approved for treatment of inflammatory bowel disease (IBD) in Canada. Although they are structurally different from infliximab, they exhibit similar physicochemical characteristics, pharmaceutical effectiveness, and immunogenicity.
Renflexis and biosimilars SB2 and CT-P13 attack tumor necrosis factor, a cytokine responsible for inflammation affecting patients with ulcerative colitis and Crohn disease. TNF inhibitors are antibodies injected into the blood stream to attack and block TNF's ability to communicate with cells, causing a reduction in inflammatory symptoms.
Development of ATIs alters circulating drug levels by making the drug inactive or increasing the rate of elimination. This makes it important to be able to know the levels of ATI.
Biosimilars to Remicade are associated with cost savings, but it must be possible to reliably monitor for circulating drug and antibody resistance, the authors wrote. The 4 assay kits used for observation were Immunodiagnostik (ALPCO), Ridascreen, Lisa Tracker, and Promonitor.
Two testing labs were used to evaluate results. The drug concentrations tested were based on the analytical measuring range of the assays and the therapeutic range of the drugs. Investigators said the assays demonstrated an acceptable linearity in the tested range for the reference biologic as well as for SB2 and CT-P13.
Although the 4 assays were originally developed for Remicade measurement, investigators said the slopes calculated through Deming regression varied by less than 10% across the three biologics for a given assay. “This gives a bias between the reference infliximab and biosimilars that is less than the usual analytical variability allowable,” suggesting that the slope variations were clinically insignificant, the authors wrote.
Researchers stress that the same evaluations should be made as other biosimilars become available, such as for adalimumab, another TNF inhibitor used to treat IBD. “Analytically biased quantification of biosimilars could lead to inappropriate dose adjustments and harm the patient.”
Reference
Neveu B, Kunst A, Prosser, C, Robitaille R. An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels [published online January 23, 2020]. Clin Biochem. doi: doi: 10.1016/j.clinbiochem.2020.01.006.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.